MX340972B - Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. - Google Patents
Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.Info
- Publication number
- MX340972B MX340972B MX2011003762A MX2011003762A MX340972B MX 340972 B MX340972 B MX 340972B MX 2011003762 A MX2011003762 A MX 2011003762A MX 2011003762 A MX2011003762 A MX 2011003762A MX 340972 B MX340972 B MX 340972B
- Authority
- MX
- Mexico
- Prior art keywords
- cells expressing
- engineered cells
- expressing multiple
- immunomodulators
- multiple immunomodulators
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 102000013462 Interleukin-12 Human genes 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940117681 interleukin-12 Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Manufacturing & Machinery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al campo de los agentes terapéuticos. Más específicamente, la invención proporciona los métodos para generar células inmunitarias manipuladas in vitro, que expresan condicionalmente interleucina 12 (IL-12) y uno o más inmunomoduladores bajo el control de un sistema de modulación de expresión en gen, en presencia del ligando de activación, y los usos para propósitos terapéuticos en animales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10381008P | 2008-10-08 | 2008-10-08 | |
PCT/US2009/005510 WO2010042189A2 (en) | 2008-10-08 | 2009-10-08 | Engineered cells expressing multiple immunomodulators and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011003762A MX2011003762A (es) | 2011-04-27 |
MX340972B true MX340972B (es) | 2016-08-02 |
Family
ID=42101134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011003762A MX340972B (es) | 2008-10-08 | 2009-10-08 | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (4) | US9492482B2 (es) |
EP (1) | EP2356219A4 (es) |
JP (3) | JP2012504959A (es) |
KR (2) | KR101629071B1 (es) |
CN (1) | CN102575227A (es) |
AU (3) | AU2009302804B2 (es) |
BR (1) | BRPI0920679A2 (es) |
CA (1) | CA2739902A1 (es) |
IL (3) | IL212184A (es) |
MX (1) | MX340972B (es) |
RU (1) | RU2573912C2 (es) |
WO (1) | WO2010042189A2 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
TWI688395B (zh) * | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
EP2681327B1 (en) * | 2011-03-04 | 2018-11-21 | Intrexon Corporation | Vectors conditionally expressing protein |
TWI586640B (zh) * | 2011-09-08 | 2017-06-11 | 英翠克頌公司 | 結晶狀二醯基肼及其用途 |
ES2795023T3 (es) * | 2011-09-16 | 2020-11-20 | Baylor College Medicine | Reconocimiento específico del microambiente tumoral mediante el uso de células NKT manipuladas |
EP3925615A1 (en) * | 2011-10-11 | 2021-12-22 | Universität Zürich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
CN102631671B (zh) * | 2012-04-05 | 2014-11-26 | 倪国颖 | 提高疫苗诱导的细胞毒性t细胞反应的治疗性疫苗 |
US10426794B2 (en) * | 2013-04-11 | 2019-10-01 | The Brigham And Women's Hospital, Inc. | Methods and compositions of treating autoimmune diseases |
SG11201508585PA (en) * | 2013-04-18 | 2015-11-27 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
DK3071697T3 (da) * | 2013-11-22 | 2020-01-27 | Dnatrix Inc | Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) |
SI3205720T1 (sl) * | 2014-10-09 | 2020-01-31 | Yamaguchi University | CAR-ekspresijski vektor in CAR-ekspresijske T-celice |
MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
SG11201704450UA (en) * | 2014-12-03 | 2017-06-29 | Anaeropharma Science Inc | Coexpression plasmid |
CN107257624B (zh) | 2014-12-09 | 2021-07-13 | 瑞泽恩制药公司 | 具有人源化分化簇274基因的非人动物 |
EP3770252A1 (en) * | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
JP6947647B2 (ja) * | 2015-02-24 | 2021-10-13 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 遺伝子改変t細胞の選択方法 |
DK3326641T3 (da) | 2015-04-22 | 2019-09-30 | Curevac Ag | Rna-holdig sammensætning til behandling af tumorsygdomme |
US20170020922A1 (en) * | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
SG11201802912PA (en) | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
CA3004742A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
SG10201913163PA (en) * | 2015-12-18 | 2020-03-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
CA3010987A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Oncolytic herpes simplex virus type 1 strain |
RU2770812C2 (ru) * | 2016-03-17 | 2022-04-22 | Ямагути Университи | Иммунокомпетентная клетка и экспрессирующий вектор, экспрессирующие регуляторные факторы иммунной функции |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
JP2018023343A (ja) * | 2016-08-12 | 2018-02-15 | 国立大学法人山口大学 | 細胞培養用培地、及び細胞培養方法 |
IL310711A (en) | 2017-01-10 | 2024-04-01 | Intrexon Corp | Modulation of expression of polypeptides through a new system for changing gene expression |
RU2740713C1 (ru) | 2017-02-28 | 2021-01-20 | Генемедицине Ко., Лтд. | Противораковая композиция, содержащая опухолеспецифический онколитический аденовирус и ингибитор контрольной точки иммунного ответа |
EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
IL270990B2 (en) | 2017-06-07 | 2024-02-01 | Precigen Inc | Expression of new cell markers |
EP3638794A4 (en) * | 2017-06-13 | 2021-03-24 | OncoSec Medical Incorporated | MULTIGEN CONSTRUCT FOR IMMUNMODULATORY PROTEIN EXPRESSION AND METHOD OF USE |
MX2020005193A (es) * | 2018-01-25 | 2020-08-20 | I Mab Biopharma Us Ltd | Fusiones de anticuerpo anti-pd-l1 e il-7. |
CN111918666A (zh) | 2018-02-02 | 2020-11-10 | Sl瓦西基因公司 | 一种新型疫苗佐剂 |
KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
CA3092935A1 (en) | 2018-03-06 | 2019-09-12 | Precigen, Inc. | Hepatitis b vaccines and uses of the same |
EP3822345A4 (en) | 2018-05-15 | 2022-06-29 | Cafa Therapeutics Limited | Genetically engineered cell and application thereof |
JP2021526826A (ja) * | 2018-06-13 | 2021-10-11 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | ウイルス検出アッセイ |
WO2020006274A1 (en) * | 2018-06-27 | 2020-01-02 | Intrexon Corporation | In vivo controlled combination therapy for treatment of cancer |
US20210317406A1 (en) * | 2018-07-09 | 2021-10-14 | The Regents Of The University Of California | Gene targets for t-cell-based immunotherapy |
EP3866813A4 (en) | 2018-10-17 | 2022-08-03 | Senti Biosciences, Inc. | COMBINATORY CANCER IMMUNOTHERAPY |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
TW202039537A (zh) * | 2018-11-27 | 2020-11-01 | 美商昂科賽克醫療公司 | 用於治療癌症之質體建構體和使用方法 |
EP3886860A4 (en) * | 2018-11-29 | 2022-08-03 | Virogin Biotech Canada Ltd | HSV VECTOR WITH REDUCED NEUROTOXICITY |
WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
CN110354260B (zh) * | 2019-08-19 | 2020-06-26 | 启辰生生物科技(珠海)有限公司 | 免疫增强剂、药物组合物及其应用 |
CN110732021B (zh) * | 2019-11-21 | 2020-08-25 | 北京启辰生生物科技有限公司 | 用于解除肿瘤免疫抑制的组合物及其应用 |
WO2021102287A1 (en) * | 2019-11-22 | 2021-05-27 | Ziopharm Oncology, Inc. | Methods of treating glioblastoma |
CN110904050B (zh) * | 2019-12-16 | 2021-02-05 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞、免疫调节组合物及应用 |
US20230270847A1 (en) * | 2020-02-18 | 2023-08-31 | Vacdiagn Biotechnology Co., Ltd. | Recombinant Viral Vector, Immunogenic Composition Comprising Same, and Uses |
CN112029730A (zh) * | 2020-05-20 | 2020-12-04 | 深圳市芥至和生物科技有限公司 | 一种基因修饰的间充质干细胞及其应用 |
WO2021251707A1 (ko) * | 2020-06-09 | 2021-12-16 | 사회복지법인 삼성생명공익재단 | Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도 |
CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
CN114426585B (zh) * | 2022-02-15 | 2023-10-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
CN115433734A (zh) * | 2022-06-01 | 2022-12-06 | 北京奇糖科技有限公司 | 核酸片段及其在制备肿瘤疫苗中的应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
ES2111289T5 (es) | 1993-01-21 | 2005-07-16 | President And Fellows Of Harvard College | Metodos y kits de diagnostico que emplean promotores de estres en mamiferos para determinar la toxicidad de un compuesto. |
US5698413A (en) | 1993-05-05 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of evaluating chemotherapeutic agents in vivo |
US20040265288A1 (en) | 1995-03-08 | 2004-12-30 | Gilman Michael Z. | New applications of gene therapy technology |
US5744304A (en) | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
US6306649B1 (en) | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
US20040086494A1 (en) | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
EP0935657B1 (en) | 1996-10-29 | 2007-08-29 | Baylor College Of Medicine | Modified steroid hormone receptors |
US20040103448A1 (en) | 1997-09-05 | 2004-05-27 | Anders Bjorklund | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
JP2001523480A (ja) | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
US7279565B2 (en) | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
JP4768916B2 (ja) | 1998-09-15 | 2011-09-07 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入 |
AU1523900A (en) | 1998-11-20 | 2000-06-13 | Valentis, Inc. | Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
CA2404253C (en) | 2000-03-22 | 2014-05-13 | Rohm And Haas Company | Novel ecdysone receptor-based inducible gene expression system |
EP1326969B1 (en) * | 2000-09-25 | 2009-04-15 | Genetronics, Inc. | Improved system for regulation of transgene expression |
US20030180719A1 (en) | 2001-04-13 | 2003-09-25 | Thomas Herget | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
WO2002086064A2 (en) | 2001-04-20 | 2002-10-31 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
US20030221203A1 (en) | 2001-10-03 | 2003-11-27 | Agha-Mohammadi Siamak | High efficiency regulatable gene expression system |
JP2005515192A (ja) * | 2001-11-29 | 2005-05-26 | ダンドリット バイオテック アクティーゼルスカブ | ヒト又は動物において免疫応答を誘導するための医薬組成物 |
GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
CN1705744A (zh) | 2002-10-14 | 2005-12-07 | 豪夫迈-罗氏公司 | 具有免疫调节剂的可移植细胞 |
ES2543084T3 (es) * | 2003-02-18 | 2015-08-14 | Baylor College Of Medicine | Activación inducida en células dendríticas |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7939061B2 (en) | 2003-02-28 | 2011-05-10 | Micropharma Limited | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
RU2358753C2 (ru) | 2003-08-07 | 2009-06-20 | Хилор Лтд. | Фармацевтические композиции и способы для ускорения заживления ран |
WO2005033297A1 (en) | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
WO2005099773A1 (en) | 2004-04-05 | 2005-10-27 | University Of Vermont And State Agricultural College | Use of erythropoietin for treatment of cancer |
US7704714B2 (en) | 2004-07-26 | 2010-04-27 | Agency For Science, Technology & Research | Encapsulation of cells in biologic compatible scaffolds by coacervation of charged polymers |
US20060067942A1 (en) | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
DOP2006000116A (es) | 2005-05-19 | 2007-01-31 | Schering Ag | Sistema mejorado de expresión regulada y sus usos. |
US7868159B2 (en) | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US20070036770A1 (en) | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
EP1951285A2 (en) | 2005-11-18 | 2008-08-06 | Ares Trading S.A. | Interferon in influenza |
WO2007078922A2 (en) | 2005-12-30 | 2007-07-12 | Neurotech Usa Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
US20080181874A1 (en) | 2007-01-29 | 2008-07-31 | Alexander Kharazi | Cell composition and method for treating cancer |
US20080241100A1 (en) | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
BRPI0811348B1 (pt) | 2007-05-29 | 2022-02-08 | Intrexon Corporation | Composto, (n-(1-ter-butil-butil)-n'-(2-etil-3-metóxi benzoil)-hidrazida de ácido (r)-3,5-dimetilbenzóico e composição farmacêutica |
WO2009009115A2 (en) | 2007-07-11 | 2009-01-15 | Nevsky Pharmaceutical Development | Liposome compositions for treatment of hepatitis c |
MX2010001993A (es) | 2007-08-23 | 2010-03-11 | Intrexon Corp | Metodos y composiciones para diagnosticar una enfermedad. |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
EP2207874B1 (en) | 2007-10-08 | 2014-12-03 | Intrexon Corporation | Engineered dendritic cells and uses for the treatment of cancer |
TWI688395B (zh) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
-
2009
- 2009-10-08 BR BRPI0920679A patent/BRPI0920679A2/pt not_active IP Right Cessation
- 2009-10-08 MX MX2011003762A patent/MX340972B/es active IP Right Grant
- 2009-10-08 AU AU2009302804A patent/AU2009302804B2/en not_active Ceased
- 2009-10-08 EP EP09819559.7A patent/EP2356219A4/en not_active Withdrawn
- 2009-10-08 JP JP2011531018A patent/JP2012504959A/ja not_active Withdrawn
- 2009-10-08 CN CN200980150164XA patent/CN102575227A/zh active Pending
- 2009-10-08 WO PCT/US2009/005510 patent/WO2010042189A2/en active Application Filing
- 2009-10-08 KR KR1020137025903A patent/KR101629071B1/ko active IP Right Grant
- 2009-10-08 CA CA2739902A patent/CA2739902A1/en not_active Abandoned
- 2009-10-08 US US13/123,129 patent/US9492482B2/en active Active
- 2009-10-08 KR KR1020117010348A patent/KR101361416B1/ko active IP Right Grant
- 2009-10-08 RU RU2011113660/10A patent/RU2573912C2/ru not_active IP Right Cessation
-
2011
- 2011-04-06 IL IL212184A patent/IL212184A/en active IP Right Grant
-
2015
- 2015-08-07 JP JP2015157352A patent/JP2016025858A/ja not_active Withdrawn
- 2015-09-30 AU AU2015234302A patent/AU2015234302B2/en not_active Ceased
- 2015-10-06 US US14/876,126 patent/US20160089398A1/en not_active Abandoned
- 2015-10-25 IL IL242254A patent/IL242254A0/en unknown
-
2016
- 2016-09-26 US US15/275,943 patent/US10046049B2/en not_active Expired - Fee Related
-
2017
- 2017-05-16 AU AU2017203273A patent/AU2017203273A1/en not_active Abandoned
- 2017-08-14 IL IL253985A patent/IL253985B/en active IP Right Grant
-
2018
- 2018-05-24 US US15/988,333 patent/US20180333486A1/en not_active Abandoned
- 2018-09-05 JP JP2018166324A patent/JP2019000118A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340972B (es) | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. | |
MX2010003720A (es) | Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer. | |
MX2018008829A (es) | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. | |
PH12019501262A1 (en) | Modified guide rnas | |
PH12020552100A1 (en) | Modified guide rnas for gene editing | |
EP3450568A3 (en) | Vectors conditionally expressing protein | |
MY159971A (en) | Multipotent/pluripotent cells and methods | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
EP3555296A4 (en) | METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN MODIFIED CELLS IN VITRO AND IN VIVO | |
MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
MX2016003636A (es) | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. | |
IN2012DN00568A (es) | ||
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
UA109418C2 (uk) | Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот | |
NZ584848A (en) | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof | |
MX2016003943A (es) | Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer. | |
MX2009008918A (es) | Activacion de celulas que presentan antigeno humano a traves de clec-6. | |
PH12014501429A1 (en) | Differentiation of human embryonic stem cells into single hormonal insulin positive cells | |
IN2015DN02826A (es) | ||
MX340952B (es) | Diferenciacion de celulas madre embrionarias humanas. | |
MX357418B (es) | Vectores de terapia genica y citosina deaminasas. | |
MX2010005317A (es) | Polipeptidos de insulina modificados y sus usos. | |
MY175954A (en) | Light-sensitive ion-passing molecules | |
AU2013312359A8 (en) | Genetically modified non-human animals and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |